

# S. K. BANSAL & CO.

CHARTERED ACCOUNTANTS

Kothi No. : 3193, Sector 28-D,

Chandigarh-160 002

E-mail : skbansalandco@gmail.com

Website : www.bansals.in

Phones : Off. : 2657202

2651578

2657644

Fax : 2652428

## **Limited Review Report to the Board of Directors**

We have reviewed the accompanying statement of unaudited financial results as enclosed of **M/s Parabolic Drugs Limited having Registered Office at SCO 99-100, Top Floor, Sector-17B, Chandigarh for the Quarter/three months ended 30<sup>th</sup> June 2016** except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.


We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above subject to Annexure-A, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

**Chandigarh;**

**Dated: 13<sup>th</sup> August 2016**

**FOR S.K. BANSAL & CO.,  
CHARTERED ACCOUNTANTS  
FRN No.002222N**



**(S.K.Bansal)**

**Membership No: 013147**

**Annexure A**

**Notes on the Un audited financial results of M/s Parabolic Drugs Limited**

**For the Quarter/Three months ended 30<sup>th</sup> June 2016**

1. Debit or Credit Balances on whatever account are subject to confirmation.
2. Depreciation has been provided for on pro-rata basis as per Companies Act, 2013.
3. Figures of the previous year/Quarter/Three months have been rearranged/regrouped wherever considered necessary.

**Chandigarh;**  
**Dated: 13th August 2016**

**FOR S.K. BANSAL & CO.,**  
**CHARTERED ACCOUNTANTS**  
**FRN No.002222N**

  
**(S.K.Bansal)**  
**Membership No: 013147**





# PARABOLIC DRUGS LTD.

(An ISO 14001 - 2004 Certified Company)



## Statement of un - audited Financial Results for the Quarter ended 30th June, 2016

(Rs. Crores)

Particulars	Three months ended 30/06/2016	Preceding Three months ended 31/03/2016	Corresponding Three months Ended 30/06/2015	Year to date figures for Current Year ended 31/03/2016
	Unaudited Stand-alone	Audited Stand-alone	Unaudited Stand-alone	Audited Stand-alone
<b>Income from Operations</b>				
Gross Sales	12.03	14.74	24.18	83.10
Less : Excise Duty	(1.18)	(1.51)	(2.63)	(8.88)
(a) Net Sales/Income from Operations (Net of excise duty)	10.85	13.23	21.55	74.22
(b) Other Operating Income	0.30	0.34	0.51	1.68
<b>Total Income from Operations (net)</b>	<b>11.15</b>	<b>13.57</b>	<b>22.06</b>	<b>75.90</b>
<b>Expenses</b>				
(a) Cost of Materials Consumed	11.94	14.78	13.98	58.20
(b) Changes in Inventories of finished goods, work-in-progress and stock-in-trade	26.25	51.67	32.03	270.31
(c) Employee Benefits Expense	1.74	2.24	2.85	10.68
(d) Depreciation & Amortisation Expense	13.38	15.81	17.08	67.06
(e) Other Expenses (Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	3.26	24.15	7.27	42.79
<b>Total Expenses</b>	<b>56.56</b>	<b>108.65</b>	<b>73.20</b>	<b>449.04</b>
Profit/(Loss) from Operations before Other Income, Finance Costs & Exceptional Items (1-2)	(45.42)	(95.08)	(51.14)	(373.14)
Other Income	-	-	-	-
<b>Profit/(Loss) from ordinary activities before finance costs and exceptional items (3 + 4)</b>	<b>(45.42)</b>	<b>(95.08)</b>	<b>(51.14)</b>	<b>(373.14)</b>
Finance Costs	31.89	28.33	25.70	107.62
Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5-6)	(77.31)	(123.41)	(76.84)	(480.76)
Exceptional Items	-	-	-	-
Profit/(Loss) from Ordinary Activities before tax (7 + 8)	(77.31)	(123.41)	(76.84)	(480.76)
Tax expense	-	4.43	-	4.43
Net Profit/(Loss) from Ordinary Activities after tax (9 - 10)	(77.31)	(127.84)	(76.84)	(485.19)
Extra Ordinary Items (net of tax expense)	-	-	-	-
<b>Net Profit / (Loss) for the period (11-12)</b>	<b>(77.31)</b>	<b>(127.84)</b>	<b>(76.84)</b>	<b>(485.19)</b>
Share of Profit/(Loss) of Associates	-	-	-	-
Minority Interest	-	-	-	-
<b>Net Profit/(Loss) after taxes, minority interest and share of profit/(loss) of Associates (13 +14 + 15)</b>	<b>(77.31)</b>	<b>(127.84)</b>	<b>(76.84)</b>	<b>(485.19)</b>
Paid-up equity share capital (Face Value of the Share shall be indicated) (Rs. 10/- each)	61.89	61.89	61.89	61.89
Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year				(283.96)
Earnings Per Share (EPS) (before extraordinary items) -Shares of Rs. 10/- each (not annualised)				

Regd. & Corp. Office : S.C.O. 99 - 100, Top Floor, Sector 17 - B, Chandigarh - 160 017 (India) Tel. : +91-172-3914646, 3914647


R & D Centre : 280-281, HSIIDC, Tehsil Barwala, District Panchkula (Hry.) India Tel. : +91-1733-256380

Works - I : Village Sundhran, P.O. Mubarakpur, Derabassi (Pb.) India Tel. : +91-1762-308657

Works - II : 45, Industrial Area, Phase II, Panchkula (Hry.) India Tel. : +91-172-2591443

Works - III : Village Chachrauli, Tehsil Derabassi, Lalru, Distt. Mohali (Pb.) Tel. : +91-1762-308792

CIN No. : L24231CH1996PLC017755.



website : www.parabolicdrugs.com



# PARABOLIC DRUGS LTD.

(An ISO 14001 - 2004 Certified Company)



(a) Basic	(12.49)	(20.66)	(12.42)	(78.40)
(b) Diluted	(12.49)	(20.66)	(12.42)	(78.40)
Earnings Per Share (EPS) (after extraordinary items) - Shares of Rs. 10/- each (not annualised)				
(a) Basic	(12.49)	(20.66)	(12.42)	(78.40)
(b) Diluted	(12.49)	(20.66)	(12.42)	(78.40)
<b>PARTICULARS OF SHAREHOLDING</b>				
Public Shareholding :				
- Number of Shares	37974587	37974587	37974587	37974587
- Percentage of Shareholding	61.36	61.36	61.36	61.36
Promoters and Promoter Group Shareholding :				
(a) Pledged/Encumbered				
- Number of shares	22619927	22619927	22619927	22619927
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	94.58	94.58	94.58	94.58
- Percentage of shares (as a % of the total share capital of the company)	36.55	36.55	36.55	36.55
(b) Non-Encumbered				
- Number of shares	1,297,500	1,297,500	1,297,500	1,297,500
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	5.42	5.42	5.42	5.42
- Percentage of shares (as a % of the total share capital of the company)	2.10	2.10	2.10	2.10

INVESTOR COMPLAINTS	Quarter ended 30/06/2016
Pending at the beginning of the quarter	Nil
Received during the quarter	Nil
Disposed of during the quarter	Nil
Remaining unresolved at the end of the quarter	Nil
<b>TOTAL</b>	<b>Nil</b>

### Notes :

- The above quarterly results have been reviewed by the Audit Committee and taken on record by the Board of Directors in their meeting held on 13th August 2016 and the same have been audited by the Statutory Auditors, as required under Clause 41 of the Listing Agreement.
- During the period under review, the company has incurred loss. Owing to the tightened market conditions and economic stress, the company has witnessed an erosion in the margins of key products.
- There is not more than one reportable segment, hence, information as per AS-17 is not required to be disclosed.
- During the quarter ended 30.06.2016, most of the banks have not charged interest due to NPA classification. Therefore the company has made provision of bank interest amounting to Rs 25.92 crores @10.50% per annum for the quarter in respect of such loan accounts.
- Figures of the previous year / period have been rearranged/regrouped wherever considered necessary.
- Promoters shareholding (22619927 shares) has been pledged pursuant to the terms of CDR package

For Parabolic Drugs Ltd.

Pranav Gupta  
Managing Director

Place : Chandigarh  
Date : 13th Aug, 2016

Regd. & Corp. Office : S.C.O. 99 - 100, Top Floor, Sector 17 - B, Chandigarh - 160 017 (India) Tel. : +91-172-3914646, 3914647

R & D Centre : 280-281, HSIIDC, Tehsil Barwala, District Panchkula (Hry.) India Tel. : +91-1733-256380

Works - I : Village Sundhran, P.O. Mubarakpur, Derabassi (Pb.) India  
Tel. : +91-1762-308657

Works - II : 45, Industrial Area, Phase II, Panchkula (Hry.) India  
Tel. : +91-172-2591443

Works - III : Village Chachrauli, Tehsil Derabassi, Lalru, Distt. Mohali (Pb.)  
Tel. : +91-1762-308792

CIN No. : L24231CH1996PLC017755.

website : www.parabolicdrugs.com